More October, 2004 pharmacogenomics journal articles.- Genotyping technologies: application to biotransformation enzyme genetic polymorphism screening.
by Romkes M, Buch SC.
Journal: Methods Mol Biol. 291:399-414
- Association study of myo-inositol monophosphatase 2 (IMPA2) polymorphisms with bipolar affective disorder and response to lithium treatment.
by Dimitrova A, Milanova V, Krastev S, Nikolov I, Toncheva D, Owen MJ, Kirov G.
Journal: Pharmacogenomics J. 10 2004;:
- Will tomorrow's medicines work for everyone?
by Tate SK, Goldstein DB.
Journal: Nat Genet. 36(11 Suppl):S34-42
- Optimized antiretroviral therapy: the role of therapeutic drug monitoring and pharmacogenomics.
by van Heeswijk RP.
Journal: Expert Rev Anti Infect Ther. 1(1):75-81
- Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.
by Clark JJ, Cools J, Curley DP, Yu JC, Lokker NA, Giese NA, Gilliland DG.
Journal: Blood. 104(9):2867-72
- Toward the pharmacogenomics of cystic fibrosis - an update.
by Sangiuolo F, D'Apice MR, Gambardella S, Di Daniele N, Novelli G.
Journal: Pharmacogenomics. 5(7):861-78
- Pharmacogenetics of selective serotonin reuptake inhibitor response: a 6-month follow-up.
by Serretti A, Zanardi R, Franchini L, Artioli P, Dotoli D, Pirovano A, Smeraldi E.
Journal: Pharmacogenetics. 14(9):607-13
- Human genetic banking: altruism, benefit and consent.
by Williams G, Schroeder D.
Journal: New Genet Soc. 23(1):89-103
- Genetic association studies in epilepsy: "the truth is out there".
by Tan NC, Mulley JC, Berkovic SF.
Journal: Epilepsia. 45(11):1429-42
- The wild genetic goose chase: Neil Holtzman talks about genetics and medicine [interview by Brandon Keim].
by Holtzman N.
Journal: Genewatch. 2004 Jul-Aug;17(4):6-10
- Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism.
by Tiwari AK, Deshpande SN, Rao AR, Bhatia T, Mukit SR, Shriharsh V, Lerer B, Nimagaonkar VL, Thelma BK.
Journal: Pharmacogenomics J. 10 2004;:
- Targeted therapies for cancer 2004.
by Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, Stagliano NE, Ginsburg GS, Symmans WF, Pusztai L, Hortobagyi GN.
Journal: Am J Clin Pathol. 122(4):598-609
- Pharmacogenomics and drug response in cardiovascular disorders.
by Siest G, Jeannesson E, Berrahmoune H, Maumus S, Marteau JB, Mohr S, Visvikis S.
Journal: Pharmacogenomics. 5(7):779-802
- Individual response to treatment: is it a valid assumption?
by Senn S.
Journal: BMJ. 329(7472):966-8
- Genetic approaches to solving common diseases.
by Abou-Sleiman PM, Healy DG, Wood NW.
Journal: J Neurol. 251(10):1169-72
- Pharmacogenomics and colorectal cancer.
by
Journal: Ann Oncol. 15(suppl_4):iv173-iv177
- Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients.
by Redon J, Luque-Otero M, Martell N, Chaves FJ.
Journal: Pharmacogenomics J. 10 2004;:
- Pharmacogenomics of adrenoceptors.
by Flordellis C, Paris H, Karabinis A, Lymperopoulos A.
Journal: Pharmacogenomics. 5(7):803-17
- Clinical and functional consequences of platelet membrane glycoprotein polymorphisms.
by Yee DL, Bray PF.
Journal: Semin Thromb Hemost. 30(5):591-600
- Microarrays in pharmacogenomics.
by Chen JJ.
Journal: J Biopharm Stat. 14(3):535-7
More pharmacogenomics journal articles ... |